



Submitted: 06.07.2021
Accepted: 06.08.2021
Early publication date: 06.10.2021

Endokrynologia Polska
DOI: 10.5603/EPa2021.0088
ISSN 0423–104X, e-ISSN 2299–8306
Volume/Tom 73; Number/Numer 1/2022

The outstanding beneficial roles of irisin disorders

Saadet Ilcin¹, Sermin Algul¹, Oguz Ozcelik²

¹Department of Physiology, Faculty of Medicine, Van Yuzuncu Yil University, Van, Turkey

²Department of Physiology, Faculty of Medicine, Kastamonu University, Kastamonu, Turkey

Abstract

Depression is a widely observed psychiatric disorder that affects a quite large number of people all around the world. A major depressive disorder (MDD) is a multifactorial disease that is associated with fluctuations in appetite, body weight, and energy situations in addition to serious mood problems. The aim of this review is to investigate a possible link between energy regulatory hormones of irisin and depressive disorders.

Irisin is a hormone that plays a significant role in the regulation of lipid and glucose metabolism in skeletal muscle and adipose tissue. Irisin was also reported to play significant roles in the central nervous system. In the literature there are reports indicating a beneficial antidepressant role of irisin in MDD. It should be emphasized that the antidepressive effects of exercise could be the result of exercise-induced increased hormones of irisin. (*Endokrynol Pol* 2022; 73 (1): 149–156)

Key words: irisin; major depressive disorders; FNDC5; type 2 diabetes mellitus; obesity

Introduction

Depression/major depressive disorder (MDD) is a disease that has genetic, biochemical, and neurophysiological causes and consequences, and is characterized by feelings such as nervousness, insecurity, hopelessness, worthlessness, and guilt. In addition, symptoms such as decreased ability to concentrate and think, decreased or increased appetite, weight loss or weight gain, insomnia or hypersomnia, low energy, fatigue or increased agitation, decreased interest in pleasurable stimuli (anhedonia), and recurrent thoughts of death and suicide may occur. It is a mood disorder [1, 2]. In 2008, the World Health Organization stated that MDD held third place worldwide in terms of disease burden but predicted that it will be in first place by 2030 [3]. The general prevalence of MDD in society is 15%; it is one of the most common psychiatric disorders in women, with a rate of 25%. With the COVID-19 virus outbreak in 2020, these rates have increased significantly, with many researchers reporting a sudden increase in stress, anxiety, and depression and a further progression of existing psychiatric disorders [4–7]. The potential roles of energy regulatory hormones in patients with depressive disorders and neuropsychiatric function have become a topic of interest in clinical medicine [8, 9]. Irisin is a recently discovered muscle-released myokine, and its relationship with depression, as well

as many other diseases, is being investigated. This review aims to examine the physiological relationship between 2 phenomena that have attracted attention, especially recently.

The history of irisin

Irisin was discovered in 2012 as a hormone released from the muscle cells of transgenic mice encoding a gene in a genomic study examining the PPARGC1A gene [10]. The Ppargc1a gene is responsible for encoding the peroxisome proliferator-activated receptor gamma coactivator 1-alpha PPAR- γ co-activator-1 α (PGC-1 α) transcription cofactor, which plays a key role in various body systems [10]. In a study in the literature, when a mouse model that overexpressed PGC-1 α was studied, it strongly increased the expression of fibronectin type III domain 5 (FNDC5) proteins. Later, it was understood that this myokine, which was discovered as a thermogenic protein that causes energy expenditure by turning white adipose tissue into brown adipose tissue, was actually released into the bloodstream by cleavage of the membrane protein called FNDC5 in the muscles. This proteolytic product with 112 amino acids, which is formed by the breakdown of 212 amino acid FNDC5 protein, is called "irisin". The name irisin comes from the name 'Iris', the messenger goddess in Greek mythology [10].



Dr. Sermin Algul, Van Yuzuncu Yil University, Faculty of Medicine, Department of Physiology, Van, Turkey, tel: +904322251701/25209; e-mail: serminalgul@hotmail.com or serminalgul@yyu.edu.tr

Biochemical structure and secretion of irisin

Irisin is a protein-structured hormone secreted from muscle tissue, with a molecular weight of 12 kDa, containing 112 amino acids [10]. This hormone-like myokine is secreted from skeletal muscle into circulation as a product of FNDC5 in response to exercise. FNDC5, which can also be referred to as FRCP2 or PeP protein, was first identified as a receptor in 2002, and it was stated to be critical for the differentiation of myoblasts and neurons [11, 12]. However, studies on FNDC5 remained scarce until the discovery of irisin.

The FNDC5 protein consists of a 209 amino acid primary structure, hydrophobic transmembrane domain, and a C-terminal domain, and it serves as a signal peptide [11]. The first 29 amino acids that make up the primary structure of mouse FNDC5 are a signal peptide, followed by the fibronectin III (FNIII) domain consisting of 94 amino acids, and the next 28 amino acids have unknown structure and function. This 28-amino-acid site contains the putative cleavage site for irisin. Next comes a 19-amino-acid transmembrane domain and a 39-amino-acid cytoplasmic domain. As a result, FNDC5 is a type I transmembrane protein the FNIII domain of which is extracellular [13]. Part of the extracellular N-terminal is cleaved and released into circulation [10]. The cleavage process of irisin derived from the extracellular domain of FNDC5 and the enzymes that mediate this process have not been fully elucidated.

The structure of irisin consists of an N-terminal FNIII-like domain attached to a flexible C-terminal tail. This area forms a continuous subunit-leaf dimer that has not been seen before [14]. It was preserved throughout the evolutionary process and is 100% similar in mice and humans [10].

In addition, irisin was accepted as an exercise-dependent myokine based on the up-regulation of FNDC5 in mouse skeletal muscle after exercise [10]. Although it is mainly found in perimysium and endomysium in skeletal muscle, it was detected in heart muscle (pericardium), brain, cerebrospinal fluid, optic nerve, tongue, and rectum and, to a lesser extent, testicles (Sertoli and Leydig cells), pancreas, liver, spleen, and stomach tissues [15, 16]. In addition, due to the presence of irisin in the cerebellum, it was suggested that the cerebellum may be a neural circuit that can regulate adipocyte metabolism and connect it to adipose tissue [17].

FNDC5 is also expressed in the brain [11, 12]. Exercise induces FNDC5 in the hippocampus dependent on PGC-1 α , which leads to increased BDNF expression [18, 19]. BDNF is a powerful regulator of neurogenesis, synaptogenesis, and synaptic plasticity [20]. In many

studies, it was stated that exercise has beneficial effects on brain health and cognitive skills and improves results in neurological conditions such as depression, epilepsy, stroke, Alzheimer's and Parkinson's disease [21–25]. Accordingly, it was suggested that the molecular mediator of exercise-dependent neurogenesis may be FNDC5/irisin.

Because of its presence in many tissues, irisin, like many other molecules, is not specific and cannot be thought of as just a myokine. In addition, it was stated in a study that it also secretes FNDC5 from white adipose tissue, so the irisin is not only a myokine but also an adipokine [26, 27]. Approximately 72% of FNDC5/irisin in circulation was previously released due to muscle secretion [28]. Exercise-induced increases of circulating irisin levels have been shown in many studies [10, 29, 30]. In addition, improved depression conditions in MDD patients following exercise programs have been reported [31, 32].

Irisin's mechanism of action

Irisin is differentiated from the FNDC5 molecule, which is membrane-bound in skeletal muscle, by the trigger of exercise and muscle movements [33]. When the N-terminal part is cleaved and released as irisin, the C-terminal domain of FNDC5 remains in the cell [33]. Irisin shows its effect on white adipose tissue by stimulating brown fat-like genes, but its receptor has not yet been discovered [10]. In addition, irisin can cross the blood-brain barrier and affect the central nervous system [34].

The first mechanism of action is that after binding to the hormone receptor, it activates the cyclic adenosine mono phosphate (cAMP), protein kinase-A (PKA), and hormone sensitive lipase (HSL)/perilipin pathway, which ensures fat breakdown. Adenylate cyclase enzyme is activated first in the cell membrane, and cAMP increase occurs inside the cell. The increasing cAMP level activates PKA. PKA induces phosphorylation of both HSL and perilipin. Perilipin is a protein found on the surface of lipid droplets that reduces fat breakdown. HSL allows the stored lipid droplets to move from the cytosol in order to lipolyze perilipin. Irisin-induced down-regulation of perilipin and up-regulation of HSL increase lipolysis [35].

The second mechanism of action is that irisin stimulates the nucleus in an unknown way, increasing UCP1 expression and blocking ATP production in the electron transport system, increasing heat production. Increased heat production with the increase of UCP1 expression increases energy expenditure in terms of glucose/fat metabolism. It also provides activation of HSL [10, 35].

Physiological effects of irisin

White and brown fat cells are different from each other. While white adipose tissue stores energy as fat, brown adipose tissue distributes energy as fatty acids and accelerates energy burning [36]. Irisin causes the white adipose tissue to convert to brown [10]. As a result of the transition from white adipose tissue to brown, fat and glucose metabolism is mainly affected. This is important because it can be associated with many metabolic disorders such as obesity and type 2 diabetes.

In addition, irisin regulates the mechanism of body temperature. In rodents, brown adipose tissue releases heat with the effect of UCP1 in thermogenesis without shivering [37]. If the heat demand cannot be met sufficiently by thermogenesis without shivering, shivering comes into play. In this way, heat begins to be produced from muscle contractions [38]. Irisin induces thermogenesis by both increasing UCP-1 expression and stimulating the browning of adipocytes. As a result, through these effects, irisin ensures energy expenditure and regulates browning of adipocytes, thermoregulation, and glucose homeostasis [10].

In addition, irisin, which is a myokine, induces genes that regulate the energy mechanism of the cell by acting on skeletal muscle, causing an increase in energy expenditure and oxidative metabolism. FNDC5 expression and release of irisin increase during myogenic differentiation in myocytes via the ERK pathway [39]; this affects the glucose metabolism by increasing glucose uptake into the muscle via GLUT4 via the AMPK α 2 pathway accompanied by p38MAPK-GLUT translocation in differentiated skeletal muscle cells [39].

Direct association of irisin and depression

Different studies are still being conducted about the possible effects of irisin. Studies on FNDC5 and PGC-1 α , from which irisin originates, constitute these possible effects. The hippocampus and ventral tegmental area (VTA), from which FNDC5 was seen to be released, was found to be effective on the proactive learning style (with the use of the reward signal) [40, 41]. The relationship between dopaminergic neurons of the mesolimbic system in the reward-related learning process is known [42]. These neurons play a role in the regulation of mood, motivation, reward, pleasure, and arousal by secreting dopamine [43]. Moreover, the rewarding effects of addictive pharmacological agents such as alcohol, nicotine, cocaine, and heroin are associated with mesolimbic dopaminergic neurons [44, 45].

In addition to its direct effect, BDNF, which increases the expression of FNDC5 the precursor of its irisin, also

plays a role in regulating the function of dopaminergic neurons. BDNF increases the dopaminergic effect by activating the presynaptic dopamine-3 receptors in VTA and the kinase B receptor associated with tropomyosin [41]. In this way, it modulates dopamine release related to neuronal plasticity, and plays an effective role in learning and memory [46]. Besides many other effects, mesolimbic dopamine plays an important role in the reward pathway, such as mediating severe social stresses [47].

Although it is still not known how BDNF affects the mesolimbic reward pathway, it was determined that activation of this pathway increases the amount of BDNF in the nucleus accumbens (NAc) and that CRF here mediates the stress transition [48]. Studies about the role/condition of the brain's mesolimbic circuitry in stress regulation and depression show that exposure to a single uncontrollable deterrent experience causes impairment in response to rewarding/deterrent stimuli and inhibition of dopamine release in rewards [49]. It was reported that chronic stressful experiences can reduce the ability of stressors by disrupting their behaviour, induce behavioural sensitivity to psychostimulants, and cause adaptive changes in mesolimbic dopamine function [49].

In a recently published study comparing athletes with a control group, the level of irisin was inversely correlated with mild depression and low-grade white matter lesions in the brain [50]. However, a study performed in obese women showed no association with depressiveness and plasma irisin levels [51].

The role of irisin in the physiopathology of depression

In order to understand the role of irisin in the pathophysiology of depression, the physiopathology of depression should be examined first. Although there are several theories about this, it is still not fully elucidated. These theories are largely based on the dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis and the hippocampus, and include neurotransmitters such as corticotropin-releasing hormone (CRH), glucocorticoids, brain-derived neurotrophic factor (BDNF), and dopamine [52].

Stress, particularly interpersonal stress, is one of the strongest proximal risk factors for depression [53]. In depressed individuals, profound differences in behaviour may occur with the onset of symptoms such as sad mood, anhedonia, decreased motivation, decreased energy level, fatigue, and social-behavioural withdrawal [47, 53]. The physiological mechanism of these behavioural changes and its relationship with irisin was investigated in many different studies.

In one study, anhedonia, one of the main symptoms of major depressive disorder (MDD), was associated with decreased sensitivity to reward [54]. In addition, Wu et al. reported that the hypermetabolism of BDNF may be a function of anhedonia rather than other features in MDD in a study comparing MDD patients with and without anhedonia [55].

In a study investigating social withdrawal/non-communication (another symptom of MDD), mice exposed to repetitive aggression displayed reluctance for social communication, and BDNF was necessary for this response [56].

In a study in the literature involving stroke patients, low serum irisin level was found to be associated with post-stroke depression (PSD) [57]. In another study with bronchial asthma patients, distress disorder (a general term that includes MDD), which is the most well-known comorbidity of bronchial asthma, was found in very few/no patients with higher serum irisin and BDNF [58]. According to these data, a high serum irisin level decreases the risk of developing MDD.

The therapeutic effect of irisin on depression

In addition to the MDD physiopathological role of irisin, its therapeutic effects were also investigated. Irisin injections were given to rats with chronic unpredictable stress. As a result of this application, irisin regulated energy metabolism in the prefrontal cortex of the brain and exerted antidepressant-like effects in rats [59]. Antidepressants work with the principle of increasing BDNF expression and preventing stress-induced BDNF decrease by increasing BDNF mRNA through 5-HT_{2A} and β -adrenoceptor subtypes. Neurotrophic factors such as BDNF or neurotrophin-3 (NT-3) increased the function of 5-HT-containing neurons in the rat brain and stimulated their growth [60]. In terms of increasing BDNF expression, irisin shows similar effects, using a similar pathway to antidepressant drugs.

Various studies were conducted on this with different patient populations. As a result of the high rate of depression in post-operative patients, irisin treatment was used in one study. It was reported that irisin reduces depressive symptoms in mice exposed to propofol used for general anaesthesia, inhibits propofol-induced neuronal cell death, and inhibits cytokine release from astrocytes [61]. In addition, epidermal growth factor receptor (EGFR), which is proven to play a role in the pathogenesis and progression of different cancer types, was reported to reduce the propofol-dependent increase in surface expression [61, 62]. In a study in the literature, mice were injected with central irisin. Likewise, an antidepressant-like effect

was achieved. In addition, it was reported to enhance the expression of PGC-1 α mRNA (which controls mitochondrial biogenesis and oxidative metabolism) in the hippocampus and prefrontal cortex [63, 64]. PGC-1 α also acts as a potent ROS removal regulatory antioxidant by increasing the expression of many ROS detoxifying enzymes, and it appears to be associated with prevention of neurodegenerative disorders such as aging [63]. This effect is also important in terms of the risk of MDD development; various experimental protocols in humans and animals showed that inflammation and neuroinflammation combined with external stimuli and neurophysiological mechanisms can trigger the formation of MDD [65]. Increasing the expression of PGC-1 α decreases both the synthesis and release of proinflammatory cytokines and glutamatergic neurotoxicity [65].

There are many studies in the literature about the relationship between MDD and physical exercise that secretes irisin. In a study conducted on patients with mild/moderate MDD, physical exercise had an antidepressant-like therapeutic effect [66]. In another study, moderate aerobic exercise was performed by MDD patients for 8 weeks; while cognitive improvements were observed in the patients, it was reported that depression scores decreased [67]. In addition, in a study comparing healthy individuals and MDD patients, subjects exercised and hippocampal activity was examined by neuroimaging methods. Exercise was found to promote neuroplasticity in both healthy and depressed brains [68]. In addition, it can increase neuronal efficiency in individuals with low compliance and cause a great mood change in patients with MDD [68]. However, contrary to the literature, in a study conducted on obese women, irisin was not associated with depression, anxiety, perceived stress level, and eating disorders [51].

Some studies reported that exercise has antidepressant-like effects. However, the mechanisms mediating this effect have not been fully explained. Possible mechanisms of action such as reducing neuroinflammation and peripheral inflammation and affecting the reward pathway in the mesolimbic cerebral were emphasized [69]. Some studies show that physical exercise promotes changes in the monoaminergic neurotransmission circuit, one of the main mechanisms of MDD and antidepressant treatments, through its effect on the release of proinflammatory cytokines [65, 70].

With recent advances, researchers examined the FNDC5 C-terminal and irisin fragment to explain this mechanism. In a study, immunohistochemical analyses and staining were performed in all hippocampal areas in mice that underwent a physical exercise protocol. There was an increase in cell proliferation, neuronal

differentiation, and neuronal survival in the dorsal and ventral dentate gyrus. In addition, the duration of immobility, one of the depressive symptoms, was reduced in mice. Finally, exercise also increased the number of FNDC5-positive cells in the hippocampal dentate gyrus and the immune content of FNDC5 C-terminal and FNDC5/irisin in the whole hippocampus. The FNDC5 C-terminal fragment/irisin pathway was reported to have an antidepressant-like, pro-neurogenic, and neuroprotective effect through treadmill running [71]. The dentate gyrus is the hippocampal area responsible for the regulation of cognitive and emotional behaviour [72]. Therefore, the increase of FNDC5/irisin in this area indicates that irisin may be effective in regulating emotional behaviour. In addition, it was suggested that the beneficial effects of physical exercise on MDD are likely to be mediated by the FNDC5/irisin pathway.

Possible relationship between irisin and depression

Due to the effects of irisin on glucose and lipid metabolism, the situation in many diseases is a topic of curiosity for many researchers and has been the subject of many studies. It was suggested that irisin, which is introduced with the “sport in the pill” discourse, can provide many of the positive effects of sports on health in a short time [10]. First of all, it was seen as a promising solution for diseases such as obesity and type-2 diabetes mellitus (T2DM) and was the subject of research. Considering that the most common diseases accompanied by depression are obesity and T2DM, a possible relationship should be examined.

Obesity, depression, and irisin

Although obesity and MDD are very common, the physical and psychiatric conditions, causal pathways, or mechanisms that link them have not yet been elucidated [73, 74]. In addition to studies suggesting that obesity causes MDD, there are studies reporting that the negative treatment of MDD triggers obesity or that they occur concurrently [74–76]. Although there are different theories about underlying factors, it was reported in the literature that there is a significant positive relationship between these 2 diseases with a high prevalence [77–79]. It would also be useful to look at the relationship between exercise, irisin, and depression in terms of obesity.

In many studies, it was found that the irisin levels of obese people are significantly reduced in terms of circulating irisin levels compared to healthy individuals [26, 80].

Some studies suggested that muscle FNDC5 gene expression in humans increased with obesity, and it was reported that irisin decreased as a result of weight loss after bariatric surgery [15, 81]. However, Huh et al. also reported that this relationship may be a compensatory mechanism [15].

Although there are many studies in the literature that examine the relationship between MDD and irisin, and obesity and irisin, there is no study that compares the relationship between MDD, obesity, and irisin, which progresses with common mechanisms.

Type 2 diabetes mellitus, depression, and irisin

A similar relationship to the obesity/MDD relationship is seen between T2DM and MDD. They have identical mechanisms feeding each other and are mutually seen as risk factors [82–84].

Contrary to studies on obesity, a study by Duran et al. found no relationship between irisin levels and body mass index. It was reported that irisin is a myokine that gradually decreases with the formation of glucose intolerance and the progression of T2DM [85]. These data were supported in many other studies; it was found that FNDC5 mRNA decreased in patients with T2DM [26] and that irisin decreased significantly [86–88].

In a study conducted in patients diagnosed with T2DM and mild cognitive impairment, the level of irisin in plasma correlated with cognitive impairment (especially executive function) in T2DM patients. Based on these results, researchers claimed that high irisin levels in plasma cause clinical early cognitive deficits in patients with T2DM [89].

However, there is no study in the literature examining the relationship between T2DM, MDD, and irisin comparatively, as in obesity.

Conclusions

Irisin may have undeniable therapeutic potential on depressive disorders. However, more clinical studies investigating the association of irisin and its effects on depression are required.

Conflict of interest

The authors have no conflicts of interest to declare.

Authors' contributions

All the authors declare that they have all participated in the design, execution, and analysis of the paper and that they have approved the final version.

References

- Belmaker RH, Agam G. Major depressive disorder. *N Engl J Med*. 2008; 358(1): 55–68, doi: [10.1056/NEJMra073096](https://doi.org/10.1056/NEJMra073096), indexed in Pubmed: [18172175](https://pubmed.ncbi.nlm.nih.gov/18172175/).
- DSM-IV-TR A. American Psychiatric Association . DSM-IV-TR A. Diagnostic and statistical manual of mental disorders. APA, Washington, DC 2000.
- Malhi G, Mann J. Depression. *Lancet*. 2018; 392(10161): 2299–2312, doi: [10.1016/S0140-6736\(18\)31948-2](https://doi.org/10.1016/S0140-6736(18)31948-2), indexed in Pubmed: [30396512](https://pubmed.ncbi.nlm.nih.gov/30396512/).
- Ozamiz-Etxebarria N, Dosal-Santamaria M, Picaza-Gorrochategui M, et al. Stress, anxiety, and depression levels in the initial stage of the COVID-19 outbreak in a population sample in the northern Spain. *Cad Saude Publica*. 2020; 36: 00054020.
- Özdin S, Bayrak Özdin Ş. Levels and predictors of anxiety, depression and health anxiety during COVID-19 pandemic in Turkish society: The importance of gender. *Int J Soc Psychiatry*. 2020; 66(5): 504–511, doi: [10.1177/0020764020927051](https://doi.org/10.1177/0020764020927051), indexed in Pubmed: [32380879](https://pubmed.ncbi.nlm.nih.gov/32380879/).
- Torales J, O'Higgins M, Castaldelli-Maia JM, et al. The outbreak of COVID-19 coronavirus and its impact on global mental health. *Int J Soc Psychiatry*. 2020; 66(4): 317–320, doi: [10.1177/0020764020915212](https://doi.org/10.1177/0020764020915212), indexed in Pubmed: [32233719](https://pubmed.ncbi.nlm.nih.gov/32233719/).
- Vindegard N, Benros ME. COVID-19 pandemic and mental health consequences: Systematic review of the current evidence. *Brain Behav Immun*. 2020; 89: 531–542, doi: [10.1016/j.bbi.2020.05.048](https://doi.org/10.1016/j.bbi.2020.05.048), indexed in Pubmed: [32485289](https://pubmed.ncbi.nlm.nih.gov/32485289/).
- Algul S, Ozcelik O. Evaluating the Levels of Nesfatin-1 and Ghrelin Hormones in Patients with Moderate and Severe Major Depressive Disorders. *Psychiatry Investig*. 2018; 15(2): 214–218, doi: [10.30773/pi.2017.05.24](https://doi.org/10.30773/pi.2017.05.24), indexed in Pubmed: [29475222](https://pubmed.ncbi.nlm.nih.gov/29475222/).
- Kim S, Choi JY, Moon S, et al. Roles of myokines in exercise-induced improvement of neuropsychiatric function. *Pflugers Arch*. 2019; 471(3): 491–505, doi: [10.1007/s00424-019-02253-8](https://doi.org/10.1007/s00424-019-02253-8), indexed in Pubmed: [30627775](https://pubmed.ncbi.nlm.nih.gov/30627775/).
- Boström P, Wu J, Jedrychowski MP, et al. A PGC1- α -dependent myokine that drives brown-fat-like development of white fat and thermogenesis. *Nature*. 2012; 481(7382): 463–468, doi: [10.1038/nature10777](https://doi.org/10.1038/nature10777), indexed in Pubmed: [22237023](https://pubmed.ncbi.nlm.nih.gov/22237023/).
- Ferrer-Martínez A, Ruiz-Lozano P, Chien KR. Mouse PeP: a novel peroxisomal protein linked to myoblast differentiation and development. *Dev Dyn*. 2002; 224(2): 154–167, doi: [10.1002/dvdy.10099](https://doi.org/10.1002/dvdy.10099), indexed in Pubmed: [12112469](https://pubmed.ncbi.nlm.nih.gov/12112469/).
- Teufel A, Malik N, Mukhopadhyay M, et al. Frp1 and Frp2, two novel fibronectin type III repeat containing genes. *Gene*. 2002; 297(1–2): 79–83, doi: [10.1016/S0378-1119\(02\)00828-4](https://doi.org/10.1016/S0378-1119(02)00828-4), indexed in Pubmed: [12384288](https://pubmed.ncbi.nlm.nih.gov/12384288/).
- Erickson HP. Irisin and FNDC5 in retrospect: An exercise hormone or a transmembrane receptor? *Adipocyte*. 2013; 2(4): 289–293, doi: [10.4161/adip.26082](https://doi.org/10.4161/adip.26082), indexed in Pubmed: [24052909](https://pubmed.ncbi.nlm.nih.gov/24052909/).
- Schumacher MA, Chinnam N, Ohashi T, et al. The structure of irisin reveals a novel intersubunit β -sheet fibronectin type III (FNIII) dimer: implications for receptor activation. *J Biol Chem*. 2013; 288(47): 33738–33744, doi: [10.1074/jbc.M113.516641](https://doi.org/10.1074/jbc.M113.516641), indexed in Pubmed: [24114836](https://pubmed.ncbi.nlm.nih.gov/24114836/).
- Huh JY, Panagiotou G, Mougios V, et al. FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. *Metabolism*. 2012; 61(12): 1725–1738, doi: [10.1016/j.metabol.2012.09.002](https://doi.org/10.1016/j.metabol.2012.09.002), indexed in Pubmed: [23018146](https://pubmed.ncbi.nlm.nih.gov/23018146/).
- Piya MK, Harte AL, Sivakumar K, et al. The identification of irisin in human cerebrospinal fluid: influence of adiposity, metabolic markers, and gestational diabetes. *Am J Physiol Endocrinol Metab*. 2014; 306(5): E512–E518, doi: [10.1152/ajpendo.00308.2013](https://doi.org/10.1152/ajpendo.00308.2013), indexed in Pubmed: [24398403](https://pubmed.ncbi.nlm.nih.gov/24398403/).
- Dun SL, Lyu RM, Chen YH, et al. Irisin-immunoreactivity in neural and non-neural cells of the rodent. *Neuroscience*. 2013; 240: 155–162, doi: [10.1016/j.neuroscience.2013.02.050](https://doi.org/10.1016/j.neuroscience.2013.02.050), indexed in Pubmed: [23470775](https://pubmed.ncbi.nlm.nih.gov/23470775/).
- Wrann CD, White JP, Salogiannis J, et al. Exercise induces hippocampal BDNF through a PGC-1 α /FNDC5 pathway. *Cell Metab*. 2013; 18(5): 649–659, doi: [10.1016/j.cmet.2013.09.008](https://doi.org/10.1016/j.cmet.2013.09.008), indexed in Pubmed: [24120943](https://pubmed.ncbi.nlm.nih.gov/24120943/).
- Xu B. BDNF (I)rising from exercise. *Cell Metab*. 2013; 18(5): 612–614, doi: [10.1016/j.cmet.2013.10.008](https://doi.org/10.1016/j.cmet.2013.10.008), indexed in Pubmed: [24206660](https://pubmed.ncbi.nlm.nih.gov/24206660/).
- Park H, Popescu A, Poo Mm. Essential role of presynaptic NMDA receptors in activity-dependent BDNF secretion and corticostriatal LTP. *Neuron*. 2014; 84(5): 1009–1022, doi: [10.1016/j.neuron.2014.10.045](https://doi.org/10.1016/j.neuron.2014.10.045), indexed in Pubmed: [25467984](https://pubmed.ncbi.nlm.nih.gov/25467984/).
- Ahlskog JE. Does vigorous exercise have a neuroprotective effect in Parkinson disease? *Neurology*. 2011; 77(3): 288–294, doi: [10.1212/WNL.0b013e318225ab66](https://doi.org/10.1212/WNL.0b013e318225ab66), indexed in Pubmed: [21768599](https://pubmed.ncbi.nlm.nih.gov/21768599/).
- Arida RM, Cavalheiro EA, da Silva AC, et al. Physical activity and epilepsy: proven and predicted benefits. *Sports Med*. 2008; 38(7): 607–615, doi: [10.2165/00007256-200838070-00006](https://doi.org/10.2165/00007256-200838070-00006), indexed in Pubmed: [18557661](https://pubmed.ncbi.nlm.nih.gov/18557661/).
- Cotman CW, Berchtold NC, Christie LA. Exercise builds brain health: key roles of growth factor cascades and inflammation. *Trends Neurosci*. 2007; 30(9): 464–472, doi: [10.1016/j.tins.2007.06.011](https://doi.org/10.1016/j.tins.2007.06.011), indexed in Pubmed: [17765329](https://pubmed.ncbi.nlm.nih.gov/17765329/).
- Russo-Neustadt A, Beard RC, Cotman CW. Exercise, antidepressant medications, and enhanced brain derived neurotrophic factor expression. *Neuropsychopharmacology*. 1999; 21(5): 679–682, doi: [10.1016/S0893-133X\(99\)00059-7](https://doi.org/10.1016/S0893-133X(99)00059-7), indexed in Pubmed: [10516964](https://pubmed.ncbi.nlm.nih.gov/10516964/).
- Zhang H, Lee JY, Borlongan CV, et al. A brief physical activity protects against ischemic stroke. *Brain Circ*. 2019; 5(3): 112–118, doi: [10.4103/bc.bc_32_19](https://doi.org/10.4103/bc.bc_32_19), indexed in Pubmed: [31620657](https://pubmed.ncbi.nlm.nih.gov/31620657/).
- Moreno-Navarrete JM, Ortega F, Serrano M, et al. Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance. *J Clin Endocrinol Metab*. 2013; 98(4): E769–E778, doi: [10.1210/jc.2012-2749](https://doi.org/10.1210/jc.2012-2749), indexed in Pubmed: [23436919](https://pubmed.ncbi.nlm.nih.gov/23436919/).
- Roca-Rivada A, Castelao C, Senin LL, et al. FNDC5/irisin is not only a myokine but also an adipokine. *PLoS One*. 2013; 8(4): e60563, doi: [10.1371/journal.pone.0060563](https://doi.org/10.1371/journal.pone.0060563), indexed in Pubmed: [23593248](https://pubmed.ncbi.nlm.nih.gov/23593248/).
- Perakakis N, Triantafyllou GA, Fernández-Real JM, et al. Physiology and role of irisin in glucose homeostasis. *Nat Rev Endocrinol*. 2017; 13(6): 324–337, doi: [10.1038/nrendo.2016.221](https://doi.org/10.1038/nrendo.2016.221), indexed in Pubmed: [28211512](https://pubmed.ncbi.nlm.nih.gov/28211512/).
- Algul S, Ozdenk C, Ozcelik O. Variations in leptin, nesfatin-1 and irisin levels induced by aerobic exercise in young trained and untrained male subjects. *Biol Sport*. 2017; 34(4): 339–344, doi: [10.5114/biol-sport.2017.69821](https://doi.org/10.5114/biol-sport.2017.69821), indexed in Pubmed: [29472736](https://pubmed.ncbi.nlm.nih.gov/29472736/).
- Ozcelik O, Algul S, Yılmaz B. Nesfatin-1 and irisin levels in response to the soccer matches performed in morning, afternoon and at night in young trained male subjects. *Cell Mol Biol (Noisy-le-grand)*. 2018; 64(10): 130–133, indexed in Pubmed: [30084805](https://pubmed.ncbi.nlm.nih.gov/30084805/).
- Brown HE, Pearson N, Braithwaite RE, et al. Physical activity interventions and depression in children and adolescents : a systematic review and meta-analysis. *Sports Med*. 2013; 43(3): 195–206, doi: [10.1007/s40279-012-0015-8](https://doi.org/10.1007/s40279-012-0015-8), indexed in Pubmed: [23329611](https://pubmed.ncbi.nlm.nih.gov/23329611/).
- Gordon BR, McDowell CP, Hallgren M, et al. Association of Efficacy of Resistance Exercise Training With Depressive Symptoms: Meta-analysis and Meta-regression Analysis of Randomized Clinical Trials. *JAMA Psychiatry*. 2018; 75(6): 566–576, doi: [10.1001/jamapsychiatry.2018.0572](https://doi.org/10.1001/jamapsychiatry.2018.0572), indexed in Pubmed: [29800984](https://pubmed.ncbi.nlm.nih.gov/29800984/).
- Lee P, Linderman JD, Smith S, et al. Irisin and FGF21 are cold-induced endocrine activators of brown fat function in humans. *Cell Metab*. 2014; 19(2): 302–309, doi: [10.1016/j.cmet.2013.12.017](https://doi.org/10.1016/j.cmet.2013.12.017), indexed in Pubmed: [24506871](https://pubmed.ncbi.nlm.nih.gov/24506871/).
- Phillips C, Baktir MA, Srivatsan M, et al. Neuroprotective effects of physical activity on the brain: a closer look at trophic factor signaling. *Front Cell Neurosci*. 2014; 8: 170, doi: [10.3389/fncel.2014.00170](https://doi.org/10.3389/fncel.2014.00170), indexed in Pubmed: [24999318](https://pubmed.ncbi.nlm.nih.gov/24999318/).
- Xiong XQ, Chen D, Sun HJ, et al. FNDC5 overexpression and irisin ameliorate glucose/lipid metabolic derangements and enhance lipolysis in obesity. *Biochim Biophys Acta*. 2015; 1852(9): 1867–1875, doi: [10.1016/j.bbdis.2015.06.017](https://doi.org/10.1016/j.bbdis.2015.06.017), indexed in Pubmed: [26111885](https://pubmed.ncbi.nlm.nih.gov/26111885/).
- Rosell M, Kaforou M, Frontini A, et al. Brown and white adipose tissues: intrinsic differences in gene expression and response to cold exposure in mice. *Am J Physiol Endocrinol Metab*. 2014; 306(8): E945–E964, doi: [10.1152/ajpendo.00473.2013](https://doi.org/10.1152/ajpendo.00473.2013), indexed in Pubmed: [24549398](https://pubmed.ncbi.nlm.nih.gov/24549398/).
- Cannon B, Nedergaard J, Zhao J, et al. Coexisting beta-adrenoceptor subtypes: significance for thermogenic process in brown fat cells. *Am J Physiol*. 1994; 267(4 Pt 1): C969–C979, doi: [10.1152/ajpcell.1994.267.4.C969](https://doi.org/10.1152/ajpcell.1994.267.4.C969), indexed in Pubmed: [7943293](https://pubmed.ncbi.nlm.nih.gov/7943293/).
- DAVIS TR, DAVIS TR. Chamber cold acclimatization in man. *Rep US Army Med Res Lab*. 1961; 475: 1–8, indexed in Pubmed: [13720246](https://pubmed.ncbi.nlm.nih.gov/13720246/).
- Li E, Li Y, Duan Y, et al. Myokines and adipokines: Involvement in the crosstalk between skeletal muscle and adipose tissue. *Cytokine Growth Factor Rev*. 2017; 33: 73–82, doi: [10.1016/j.cytogfr.2016.10.003](https://doi.org/10.1016/j.cytogfr.2016.10.003), indexed in Pubmed: [27765498](https://pubmed.ncbi.nlm.nih.gov/27765498/).
- Steiner JL, Murphy EA, McClellan JL, et al. Exercise training increases mitochondrial biogenesis in the brain. *J Appl Physiol* (1985). 2011; 111(4): 1066–1071, doi: [10.1152/jappphysiol.00343.2011](https://doi.org/10.1152/jappphysiol.00343.2011), indexed in Pubmed: [21817111](https://pubmed.ncbi.nlm.nih.gov/21817111/).
- Zsuga J, Biro K, Papp C, et al. The “proactive” model of learning: Integrative framework for model-free and model-based reinforcement learning utilizing the associative learning-based proactive brain concept. *Behav Neurosci*. 2016; 130(1): 6–18, doi: [10.1037/bne0000116](https://doi.org/10.1037/bne0000116), indexed in Pubmed: [26795580](https://pubmed.ncbi.nlm.nih.gov/26795580/).
- Schott BH, Minuzzi L, Krebs RM, et al. Mesolimbic functional magnetic resonance imaging activations during reward anticipation correlate with reward-related ventral striatal dopamine release. *J Neurosci*. 2008; 28(52): 14311–14319, doi: [10.1523/JNEUROSCI.2058-08.2008](https://doi.org/10.1523/JNEUROSCI.2058-08.2008), indexed in Pubmed: [19109512](https://pubmed.ncbi.nlm.nih.gov/19109512/).
- Leyton M. The neurobiology of desire: Dopamine and the regulation of mood and motivational states in humans. In: Kringelbach ML, Berridge KC, ed. *Pleasures of the brain*. Oxford University Press, Oxford 2010: 222–243.
- Di Chiara G. The role of dopamine in drug abuse viewed from the perspective of its role in motivation. *Drug Alcohol Depend*. 1995; 38(2): 95–137, doi: [10.1016/0376-8716\(95\)01118-1](https://doi.org/10.1016/0376-8716(95)01118-1), indexed in Pubmed: [7671769](https://pubmed.ncbi.nlm.nih.gov/7671769/).

45. Pierce RC, Kumaresan V. The mesolimbic dopamine system: the final common pathway for the reinforcing effect of drugs of abuse? *Neurosci Biobehav Rev.* 2006; 30(2): 215–238, doi: [10.1016/j.neubiorev.2005.04.016](https://doi.org/10.1016/j.neubiorev.2005.04.016), indexed in Pubmed: [16099045](https://pubmed.ncbi.nlm.nih.gov/16099045/).
46. Hymn C, Hofer M, Barde YA, et al. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. *Nature.* 1991; 350(6315): 230–232, doi: [10.1038/350230a0](https://doi.org/10.1038/350230a0), indexed in Pubmed: [2005978](https://pubmed.ncbi.nlm.nih.gov/2005978/).
47. Nestler EJ, Carlezon WA. The mesolimbic dopamine reward circuit in depression. *Biol Psychiatry.* 2006; 59(12): 1151–1159, doi: [10.1016/j.biopsych.2005.09.018](https://doi.org/10.1016/j.biopsych.2005.09.018), indexed in Pubmed: [16566899](https://pubmed.ncbi.nlm.nih.gov/16566899/).
48. Walsh JJ, Friedman AK, Sun H, et al. Stress and CRF gate neural activation of BDNF in the mesolimbic reward pathway. *Nat Neurosci.* 2014; 17(1): 27–29, doi: [10.1038/nn.3591](https://doi.org/10.1038/nn.3591), indexed in Pubmed: [24270188](https://pubmed.ncbi.nlm.nih.gov/24270188/).
49. Cabib S, Puglisi-Allegra S, Imperato A, et al. Genotype-dependent adaptation of mesolimbic dopamine system and stress-induced behavioral sensitization to amphetamine. *Clin Neuropharmacol.* 1992; 15 Suppl 1 Pt A(1-2): 251A–252A, doi: [10.1097/00002826-199201001-00131](https://doi.org/10.1097/00002826-199201001-00131), indexed in Pubmed: [1498830](https://pubmed.ncbi.nlm.nih.gov/1498830/).
50. Mucher P, Batmyagmar D, Perkmann T, et al. Basal myokine levels are associated with quality of life and depressed mood in older adults. *Psychophysiology.* 2021; 58(5): e13799, doi: [10.1111/psyp.13799](https://doi.org/10.1111/psyp.13799), indexed in Pubmed: [33655551](https://pubmed.ncbi.nlm.nih.gov/33655551/).
51. Hofmann T, Elbelt U, Ahnis A, et al. The exercise induced myokine irisin does not show an association with depressiveness, anxiety and perceived stress in obese women. *J Physiol Pharmacol.* 2016; 67: 195–203, indexed in Pubmed: [27226179](https://pubmed.ncbi.nlm.nih.gov/27226179/).
52. Opmeer EM, Kortekaas R, Aleman A. Depression and the role of genes involved in dopamine metabolism and signalling. *Prog Neurobiol.* 2010; 92(2): 112–133, doi: [10.1016/j.pneurobio.2010.06.003](https://doi.org/10.1016/j.pneurobio.2010.06.003), indexed in Pubmed: [20558238](https://pubmed.ncbi.nlm.nih.gov/20558238/).
53. Slavich GM, Irwin MR. From stress to inflammation and major depressive disorder: a social signal transduction theory of depression. *Psychol Bull.* 2014; 140(3): 774–815, doi: [10.1037/a0035302](https://doi.org/10.1037/a0035302), indexed in Pubmed: [24417575](https://pubmed.ncbi.nlm.nih.gov/24417575/).
54. Huys QJm, Pizzagalli DA, Bogdan R, et al. Mapping anhedonia onto reinforcement learning: a behavioural meta-analysis. *Biol Mood Anxiety Disord.* 2013; 3(1): 12, doi: [10.1186/2045-5380-3-12](https://doi.org/10.1186/2045-5380-3-12), indexed in Pubmed: [23782813](https://pubmed.ncbi.nlm.nih.gov/23782813/).
55. Wu C, Lu J, Lu S, et al. Increased ratio of mature BDNF to precursor-BDNF in patients with major depressive disorder with severe anhedonia. *J Psychiatr Res.* 2020; 126: 92–97, doi: [10.1016/j.jpsychires.2020.05.010](https://doi.org/10.1016/j.jpsychires.2020.05.010), indexed in Pubmed: [32428748](https://pubmed.ncbi.nlm.nih.gov/32428748/).
56. Berton O, McClung CA, Dileone RJ, et al. Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. *Science.* 2006; 311(5762): 864–868, doi: [10.1126/science.1120972](https://doi.org/10.1126/science.1120972), indexed in Pubmed: [16469931](https://pubmed.ncbi.nlm.nih.gov/16469931/).
57. Tu WJ, Qiu HC, Liu Q, et al. Decreased level of irisin, a skeletal muscle cell-derived myokine, is associated with post-stroke depression in the ischemic stroke population. *J Neuroinflammation.* 2018; 15(1): 133, doi: [10.1186/s12974-018-1177-6](https://doi.org/10.1186/s12974-018-1177-6), indexed in Pubmed: [29720216](https://pubmed.ncbi.nlm.nih.gov/29720216/).
58. Szilasi ME, Pak K, Kardos L, et al. The Alteration of Irisin-Brain-Derived Neurotrophic Factor Axis Parallels Severity of Distress Disorder in Bronchial Asthma Patients. *Front Neurosci.* 2017; 11: 653, doi: [10.3389/fnins.2017.00653](https://doi.org/10.3389/fnins.2017.00653), indexed in Pubmed: [29217995](https://pubmed.ncbi.nlm.nih.gov/29217995/).
59. Wang S, Pan J. Irisin ameliorates depressive-like behaviors in rats by regulating energy metabolism. *Biochem Biophys Res Commun.* 2016; 474(1): 22–28, doi: [10.1016/j.bbrc.2016.04.047](https://doi.org/10.1016/j.bbrc.2016.04.047), indexed in Pubmed: [27079240](https://pubmed.ncbi.nlm.nih.gov/27079240/).
60. Altar CA, Laeng P, Jurata LW, et al. Neurotrophins and depression. *Trends Pharmacol Sci.* 1999; 20(2): 59–61, doi: [10.1016/s0165-6147\(99\)01309-7](https://doi.org/10.1016/s0165-6147(99)01309-7), indexed in Pubmed: [10101965](https://pubmed.ncbi.nlm.nih.gov/10101965/).
61. Hou Z, Zhang J, Yu Ke, et al. Irisin ameliorates the postoperative depressive-like behavior by reducing the surface expression of epidermal growth factor receptor in mice. *Neurochem Int.* 2020; 135: 104705, doi: [10.1016/j.neuint.2020.104705](https://doi.org/10.1016/j.neuint.2020.104705), indexed in Pubmed: [32045617](https://pubmed.ncbi.nlm.nih.gov/32045617/).
62. Normanno N, De Luca A, Bianco C, et al. The ErbB receptors and their ligands in cancer: an overview. *Curr Drug Targets.* 2005; 6(3): 243–257, doi: [10.2174/1389450053765879](https://doi.org/10.2174/1389450053765879), indexed in Pubmed: [15857286](https://pubmed.ncbi.nlm.nih.gov/15857286/).
63. Austin S, St-Pierre J. PGC1 α and mitochondrial metabolism—emerging concepts and relevance in ageing and neurodegenerative disorders. *J Cell Sci.* 2012; 125(Pt 21): 4963–4971, doi: [10.1242/jcs.113662](https://doi.org/10.1242/jcs.113662), indexed in Pubmed: [23277535](https://pubmed.ncbi.nlm.nih.gov/23277535/).
64. Siteneski A, Cunha MP, Lieberknecht V, et al. Central irisin administration affords antidepressant-like effect and modulates neuroplasticity-related genes in the hippocampus and prefrontal cortex of mice. *Prog Neuropsychopharmacol Biol Psychiatry.* 2018; 84(Pt A): 294–303, doi: [10.1016/j.pnpbp.2018.03.004](https://doi.org/10.1016/j.pnpbp.2018.03.004), indexed in Pubmed: [29524513](https://pubmed.ncbi.nlm.nih.gov/29524513/).
65. Ignácio ZM, da Silva RS, Plissari ME, et al. Physical Exercise and Neuroinflammation in Major Depressive Disorder. *Mol Neurobiol.* 2019; 56(12): 8323–8335, doi: [10.1007/s12035-019-01670-1](https://doi.org/10.1007/s12035-019-01670-1), indexed in Pubmed: [31228000](https://pubmed.ncbi.nlm.nih.gov/31228000/).
66. Blumenthal JA, Babyak MA, Doraiswamy PM, et al. Exercise and pharmacotherapy in the treatment of major depressive disorder. *Psychosom Med.* 2007; 69(7): 587–596, doi: [10.1097/PSY.0b013e318148c19a](https://doi.org/10.1097/PSY.0b013e318148c19a), indexed in Pubmed: [17846259](https://pubmed.ncbi.nlm.nih.gov/17846259/).
67. Olson RL, Brush CJ, Ehmann PJ, et al. A randomized trial of aerobic exercise on cognitive control in major depression. *Clin Neurophysiol.* 2017; 128(6): 903–913, doi: [10.1016/j.clinph.2017.01.023](https://doi.org/10.1016/j.clinph.2017.01.023), indexed in Pubmed: [28402866](https://pubmed.ncbi.nlm.nih.gov/28402866/).
68. Gourgouvelis J, Yelder P, Murphy B. Exercise Promotes Neuroplasticity in Both Healthy and Depressed Brains: An fMRI Pilot Study. *Neural Plast.* 2017; 8305287, doi: [10.1155/2017/8305287](https://doi.org/10.1155/2017/8305287), indexed in Pubmed: [28828187](https://pubmed.ncbi.nlm.nih.gov/28828187/).
69. Phillips C, Fahimi A. Immune and Neuroprotective Effects of Physical Activity on the Brain in Depression. *Front Neurosci.* 2018; 12: 498, doi: [10.3389/fnins.2018.00498](https://doi.org/10.3389/fnins.2018.00498), indexed in Pubmed: [30093853](https://pubmed.ncbi.nlm.nih.gov/30093853/).
70. Galts CPC, Bettio LEB, Jewett DC, et al. Depression in neurodegenerative diseases: Common mechanisms and current treatment options. *Neurosci Biobehav Rev.* 2019; 102: 56–84, doi: [10.1016/j.neubiorev.2019.04.002](https://doi.org/10.1016/j.neubiorev.2019.04.002), indexed in Pubmed: [30995512](https://pubmed.ncbi.nlm.nih.gov/30995512/).
71. Siteneski A, Olescowicz G, Pazini FL, et al. Antidepressant-like and pro-neurogenic effects of physical exercise: the putative role of FNDc5/irisin pathway. *J Neural Transm (Vienna).* 2020; 127(3): 355–370, doi: [10.1007/s00702-020-02143-9](https://doi.org/10.1007/s00702-020-02143-9), indexed in Pubmed: [31974720](https://pubmed.ncbi.nlm.nih.gov/31974720/).
72. Kheirbek MA, Hen R. Dorsal vs ventral hippocampal neurogenesis: implications for cognition and mood. *Neuropsychopharmacology.* 2011; 36(1): 373–374, doi: [10.1038/npp.2010.148](https://doi.org/10.1038/npp.2010.148), indexed in Pubmed: [21116266](https://pubmed.ncbi.nlm.nih.gov/21116266/).
73. Carpenter KM, Hasin DS, Allison DB, et al. Relationships between obesity and DSM-IV major depressive disorder, suicide ideation, and suicide attempts: results from a general population study. *Am J Public Health.* 2000; 90(2): 251–257, doi: [10.2105/ajph.90.2.251](https://doi.org/10.2105/ajph.90.2.251), indexed in Pubmed: [10667187](https://pubmed.ncbi.nlm.nih.gov/10667187/).
74. Faith MS, Matz PE, Jorge MA. Obesity-depression associations in the population. *J Psychosom Res.* 2002; 53(4): 935–942, doi: [10.1016/s0022-3999\(02\)00308-2](https://doi.org/10.1016/s0022-3999(02)00308-2), indexed in Pubmed: [12377306](https://pubmed.ncbi.nlm.nih.gov/12377306/).
75. Kloiber S, Ising M, Reppermund S, et al. Overweight and obesity affect treatment response in major depression. *Biol Psychiatry.* 2007; 62(4): 321–326, doi: [10.1016/j.biopsych.2006.10.001](https://doi.org/10.1016/j.biopsych.2006.10.001), indexed in Pubmed: [17241618](https://pubmed.ncbi.nlm.nih.gov/17241618/).
76. Onyike CU, Crum RM, Lee HB, et al. Is obesity associated with major depression? Results from the Third National Health and Nutrition Examination Survey. *Am J Epidemiol.* 2003; 158(12): 1139–1147, doi: [10.1093/aje/kwg275](https://doi.org/10.1093/aje/kwg275), indexed in Pubmed: [14652298](https://pubmed.ncbi.nlm.nih.gov/14652298/).
77. Blaine B. Does depression cause obesity?: A meta-analysis of longitudinal studies of depression and weight control. *J Health Psychol.* 2008; 13(8): 1190–1197, doi: [10.1177/1359105308095977](https://doi.org/10.1177/1359105308095977), indexed in Pubmed: [18987092](https://pubmed.ncbi.nlm.nih.gov/18987092/).
78. de Wit L, Luppino F, van Straten A, et al. Depression and obesity: a meta-analysis of community-based studies. *Psychiatry Res.* 2010; 178(2): 230–235, doi: [10.1016/j.psychres.2009.04.015](https://doi.org/10.1016/j.psychres.2009.04.015), indexed in Pubmed: [20462641](https://pubmed.ncbi.nlm.nih.gov/20462641/).
79. Luppino FS, de Wit LM, Bouvy PF, et al. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. *Arch Gen Psychiatry.* 2010; 67(3): 220–229, doi: [10.1001/archgenpsychiatry.2010.2](https://doi.org/10.1001/archgenpsychiatry.2010.2), indexed in Pubmed: [20194822](https://pubmed.ncbi.nlm.nih.gov/20194822/).
80. Hou N, Han F, Sun X. The relationship between circulating irisin levels and endothelial function in lean and obese subjects. *Clin Endocrinol (Oxf).* 2015; 83(3): 339–343, doi: [10.1111/cen.12658](https://doi.org/10.1111/cen.12658), indexed in Pubmed: [25382211](https://pubmed.ncbi.nlm.nih.gov/25382211/).
81. Timmons JA, Baar K, Davidsen PK, et al. Is irisin a human exercise gene? *Nature.* 2012; 488(7413): E9–10; discussion E10, doi: [10.1038/nature11364](https://doi.org/10.1038/nature11364), indexed in Pubmed: [22932392](https://pubmed.ncbi.nlm.nih.gov/22932392/).
82. Knol MJ, Twisk JWR, Beekman ATF, et al. Depression as a risk factor for the onset of type 2 diabetes mellitus. A meta-analysis. *Diabetologia.* 2006; 49(5): 837–845, doi: [10.1007/s00125-006-0159-x](https://doi.org/10.1007/s00125-006-0159-x), indexed in Pubmed: [16520921](https://pubmed.ncbi.nlm.nih.gov/16520921/).
83. Mezuk B, Eaton WW, Albrecht S, et al. Depression and type 2 diabetes over the lifespan: a meta-analysis. *Diabetes Care.* 2008; 31(12): 2383–2390, doi: [10.2337/dc08-0985](https://doi.org/10.2337/dc08-0985), indexed in Pubmed: [19033418](https://pubmed.ncbi.nlm.nih.gov/19033418/).
84. Nefs G, Pouwer F, Denollet J, et al. The course of depressive symptoms in primary care patients with type 2 diabetes: results from the Diabetes, Depression, Type D Personality Zuidoost-Brabant (DiaDDZoB) Study. *Diabetologia.* 2012; 55(3): 608–616, doi: [10.1007/s00125-011-2411-2](https://doi.org/10.1007/s00125-011-2411-2), indexed in Pubmed: [22198261](https://pubmed.ncbi.nlm.nih.gov/22198261/).
85. Duran ID, Gülgelik NE, Ünal M, et al. Irisin levels in the progression of diabetes in sedentary women. *Clin Biochem.* 2015; 48(18): 1268–1272, doi: [10.1016/j.clinbiochem.2015.07.098](https://doi.org/10.1016/j.clinbiochem.2015.07.098), indexed in Pubmed: [26234637](https://pubmed.ncbi.nlm.nih.gov/26234637/).
86. Du XL, Jiang WX, Lv ZT. Lower Circulating Irisin Level in Patients with Diabetes Mellitus: A Systematic Review and Meta-Analysis. *Horm Metab Res.* 2016; 48(10): 644–652, doi: [10.1055/s-0042-108730](https://doi.org/10.1055/s-0042-108730), indexed in Pubmed: [27300472](https://pubmed.ncbi.nlm.nih.gov/27300472/).
87. Liu JJ, Wong MDS, Toy WC, et al. Lower circulating irisin is associated with type 2 diabetes mellitus. *J Diabetes Complications.* 2013; 27(4):

- 365–369, doi: [10.1016/j.jdiacomp.2013.03.002](https://doi.org/10.1016/j.jdiacomp.2013.03.002), indexed in Pubmed: [23619195](https://pubmed.ncbi.nlm.nih.gov/23619195/).
88. Yan B, Shi X, Zhang H, et al. Association of serum irisin with metabolic syndrome in obese Chinese adults. *PLoS One*. 2014; 9(4): e94235, doi: [10.1371/journal.pone.0094235](https://doi.org/10.1371/journal.pone.0094235), indexed in Pubmed: [24709991](https://pubmed.ncbi.nlm.nih.gov/24709991/).
89. Lin H, Yuan Y, Tian S, et al. In Addition to Poor Glycemic Control, a High Level of Irisin in the Plasma Portends Early Cognitive Deficits Clinically in Chinese Patients With Type 2 Diabetes Mellitus. *Front Endocrinol (Lausanne)*. 2019; 10: 634, doi: [10.3389/fendo.2019.00634](https://doi.org/10.3389/fendo.2019.00634), indexed in Pubmed: [31572306](https://pubmed.ncbi.nlm.nih.gov/31572306/).